Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Sponsors › Genomics: Clinical Implementation › Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

Presence of cfDNA, CTCs Predicts Recurrence in Triple-Negative Breast Cancer

Jul 10, 2020
|
staff reporter

NEW YORK – A combined method measuring both circulating tumor DNA and circulating tumor cells can detect lingering residual disease in women with triple-negative breast cancer after neoadjuvant chemotherapy and predicts disease recurrence, according to a new study.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
27
Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Sponsored by
LGC SeraCare Life Sciences

This webinar features a panel of industry stakeholders in cancer diagnostics, proficiency testing and clinical care who will discuss the promise and challenges of liquid biopsy technologies in disease diagnosis, monitoring, and patient care management.

Oct
29
Featured Webinar

How to Train Your DRAGEN for Pathology Informatics

Illumina’s BaseSpace Sequence Hub (BSSH) supports primary and secondary analysis of massively parallel sequencing data and can be applied to gene panel data that is generated as part of a clinical cancer assay performed in a pathology lab.

Nov
03
Featured Webinar

A Streamlined Targeted NGS Workflow for Comprehensive Genomic Profiling of Different Tumor Samples

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Featured Webinar

Beyond Traditional Biopsy for Esophageal Cancer: Novel Sampling Methods to Improve Patient Care

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

What's Popular?

In Cancer

  1. UK's NICE Recommends Merck's Keytruda for Head and Neck Cancer With PD-L1 Expression

  2. Genetic Testing Challenges in Oncology: Surgeon Recommends Mastectomy for Woman With RAD50 Mutation

  3. Dual Antigen CAR T-cell Therapy Shows Benefit in Medical College of Wisconsin Study

    Premium

  4. Roche, NeoImmuneTech Collaborate on NSCLC Trial Evaluating NT-17 Plus Tecentriq

  5. Allarity Pushes Back NDA Filing for Kidney Cancer Drug to 2021

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.